MiniMed Group, Inc. (MMED) fair value analysis
Nasdaq · Updated 2026-10-19
MMED price how computed
Valuation status
Awaiting full valuationMMED's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once MMED's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $17.49
- Sector
- Healthcare
- 12-month range
- $12.00–$22.42
- Market cap
- $4.92B
- From 52-week high
- -22.0%
- Shares outstanding
- 281M
- Rank in Healthcare by quality score
- #196 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
MiniMed Group, Inc. is a medical device company that develops and manufactures insulin infusion pump systems and continuous glucose monitoring devices for diabetes management. The company operates in the United States and serves patients globally through its healthcare technology products.
MMED currently ranks #196 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $4.92B
- Revenue (TTM)
- $3.22B
- Net margin
- -10.2%
- Gross margin
- 55.2%
- Debt / equity
- 0.02
- Shares outstanding
- 281M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 30 · oversold
Earnings how computed
- Last 3 quarters vs consensus
- 1 beat, 2 missed
- Quarter by quarter
- 2026-07 ▲ beat (+46.3%)
2026-04 ▼ miss (-172.7%)
2026-01 ▼ miss (-63.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 1 hold · 1 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $25.2
- Target vs last price
- +44.1%
What our data shows for MMED
- Shares are trading in the middle of their 12-month price range of $12.00–$22.42.
- The 14-day relative strength index sits at an oversold 30.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MMED's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MMED conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — MMED's relative strength index moved into oversold territory this week, shifting from a neutral zone last week. The Healthcare sector stock's derived indicators are currently in transition, with valuation assessment remaining incomplete pending further data consolidation.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MMED stock undervalued?
MMED's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is MMED's TickrTrends verdict?
MMED is currently marked 'Awaiting full valuation' - a verdict publishes automatically once MMED's own trailing P/E history validates under our standards.
How does MMED compare to other Healthcare stocks?
MMED ranks #196 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MMED overbought or oversold?
MMED's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does MMED usually beat earnings estimates?
Over its last 3 reported quarters MMED beat the consensus estimate 1 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MMED?
Of 13 analysts covering MMED, 11 rate it a buy, 1 a hold and 1 a sell - buy-leaning, with a consensus price target of $25.2 (+44.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.